Document 2337
 DOCN  M94A2337
 TI    Investigation of MAC by the HIV INSIGHT database.
 DT    9412
 AU    Fletcher P; Deresinski SC; Stavrakas S; Fisher D; IMS International,
       London, England.
 SO    Int Conf AIDS. 1994 Aug 7-12;10(1):327 (abstract no. PC0242). Unique
       Identifier : AIDSLINE ICA10/94370238
 AB    INTRODUCTION: Infection by the mycobacterium avium complex (MAC) is now
       recognized as a common complication of AIDS and is a serious
       contributory factor to morbidity and mortality. The importance of this
       condition has only been appreciated in the last 2-3 years and
       prophylaxis with antibiotics is an even more recent introduction. The
       randomized controlled clinical trial is the accepted method for the
       determination of efficacy of new treatments and may also be of limited
       value in the assessment of safety. Patient selection, relatively small
       numbers and limited duration of the studies make clinical trials
       inappropriate for the investigation of the epidemiology or the natural
       history of disease. METHODS: The HIV INSIGHT database, which contains
       the detailed clinical records of 2,700 HIV positive patients extending
       up to 10 years, can provide data of this kind in addition to information
       on drugs prescribed, dosage, durations of treatment, hospitalization,
       laboratory investigations, disease progression and length of survival.
       RESULTS/CONCLUSIONS: The clinical picture of 200+ patients who developed
       MAC will be presented. Data are drawn from a nationwide network of 40
       physicians contributing to HIV INSIGHT (55% ID's, 24% IM's, 21% Family
       Practice and Other). The changing incidence of MAC over time will be
       presented. The adoption and impact of prophylaxis will be quantified.
       Schedules of treatment and/or prophylaxis with antibiotics and
       antivirals from the time of HIV seropositivity and outcomes will be
       compared across different patterns of disease progression. Comparisons
       will also be made with a monitored control group of HIV/AIDS patients
       who did not develop MAC.
 DE    Antitubercular Agents/THERAPEUTIC USE  Antiviral Agents/THERAPEUTIC USE
       AIDS-Related Opportunistic Infections/DRUG THERAPY/*EPIDEMIOLOGY/
       MORTALITY  Clinical Trials/*STATISTICS & NUMER DATA  Human  *Information
       Systems  Mycobacterium avium-intracellulare Infection/DRUG THERAPY/
       *EPIDEMIOLOGY/MORTALITY  Survival Rate  MEETING ABSTRACT

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).